Clinical Trial

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

Study acronym: SPRINT 2
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized trial evaluating the efficacy and safety of sequential dual-agent immunotherapy and risk-adapted radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of at least 50%. Participants will be randomized between two dual-agent immunotherapy regimens: durvalumab + monalizumab versus durvalumab + oleclumab.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-12 -> 2028-04 2026-06-10
minor Completion pushed: 2028-10 -> 2029-02 2026-06-10
Trial Details
NCT Number NCT07146230
Lead Sponsor Montefiore Medical Center
Collaborators: AstraZeneca
Conditions Non-small Cell Lung Cancer
Enrollment 52 participants
Start Date 2026-09
Primary Completion 2028-04 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-09